Insider Buying: Achieve Life Sciences, Inc. (NASDAQ:ACHV) CFO Buys $28,900.00 in Stock

Achieve Life Sciences, Inc. (NASDAQ:ACHV) CFO Mark K. Oki bought 10,000 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were acquired at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the completion of the transaction, the chief financial officer now owns 10,000 shares in the company, valued at $28,900. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Achieve Life Sciences Price Performance

Shares of Achieve Life Sciences stock opened at $2.81 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.78 and a current ratio of 6.78. The firm’s 50-day simple moving average is $3.09 and its 200-day simple moving average is $3.95. Achieve Life Sciences, Inc. has a twelve month low of $2.51 and a twelve month high of $5.59. The firm has a market cap of $97.46 million, a P/E ratio of -2.49 and a beta of 1.67.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.06). As a group, research analysts expect that Achieve Life Sciences, Inc. will post -1.17 EPS for the current fiscal year.

Hedge Funds Weigh In On Achieve Life Sciences

Institutional investors have recently added to or reduced their stakes in the company. Barclays PLC lifted its holdings in Achieve Life Sciences by 303.1% during the 3rd quarter. Barclays PLC now owns 47,655 shares of the biopharmaceutical company’s stock valued at $226,000 after purchasing an additional 35,832 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in Achieve Life Sciences during the 4th quarter valued at about $49,000. Geode Capital Management LLC lifted its holdings in Achieve Life Sciences by 6.9% during the 3rd quarter. Geode Capital Management LLC now owns 749,109 shares of the biopharmaceutical company’s stock valued at $3,552,000 after purchasing an additional 48,474 shares during the last quarter. State Street Corp lifted its holdings in Achieve Life Sciences by 6.8% during the 3rd quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company’s stock valued at $2,045,000 after purchasing an additional 27,419 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Achieve Life Sciences by 74.8% during the 4th quarter. SG Americas Securities LLC now owns 19,886 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 8,512 shares during the last quarter. 33.52% of the stock is owned by institutional investors.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.